Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Trial Details

NCT ID
NCT05095207
Phase
PHASE1 / PHASE2
Sponsor
Icahn School of Medicine at Mount Sinai
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Abemaciclib
  • Bicalutamide
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
  • If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss …
  • Women aged at least 18 years
  • The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic HER2neu-negative breast cancer (including …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →